GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN TYPE 2 DIABETES MELLITUS (T2DM): DATA FROM A REAL WORLD STUDY IN SPAIN

被引：0
|
作者：
Norrbacka, K. [1 ]
Sicras-Mainar, A. [2 ]
Hernandez, I [3 ]
Tofe-Povedano, S. [4 ]
Diaz Cerezo, S. [5 ]
Artime, E. [5 ]
Lebrec, J. [6 ]
Romera, I [5 ]
机构：
[1] Eli Lilly & Co, Helsinki, Finland
[2] Real Life Data SLU, Barcelona, Spain
[3] Real Life Data SLU, Madrid, Spain
[4] Univ Hosp Son Espases Palma de Mallorca, Palma De Mallorca, Spain
[5] Lilly Spain, Alcobendas, Spain
[6] HaaPACS GmbH, Schriesheim, Germany
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB119
引用
收藏
页码：S594 / S594
页数：1
相关论文
共 50 条
  • [41] Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
    Yixing Li
    Paul D. Rosenblit
    Current Cardiology Reports, 2018, 20
  • [42] Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus
    Guyton, Justinne
    Jeon, Michelle
    Brooks, Amie
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2019, 76 (21) : 1739 - 1748
  • [43] Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes
    De Block, Christophe E. M.
    Dirinck, Eveline
    Verhaegen, Ann
    Van Gaal, Luc F.
    DIABETES OBESITY & METABOLISM, 2022, 24 (05): : 788 - 805
  • [44] Initiating a Glucagon-like Peptide-1 Receptor Agonist in the Management of Type 2 Diabetes Mellitus
    Gavin, James R., III
    JOURNAL OF THE AMERICAN OSTEOPATHIC ASSOCIATION, 2012, 112 (01): : S16 - S21
  • [45] Is secretion of glucagon-like peptide-1 reduced in type 2 diabetes mellitus?
    Juris J Meier
    Michael A Nauck
    Nature Clinical Practice Endocrinology & Metabolism, 2008, 4 : 606 - 607
  • [46] Is secretion of glucagon-like peptide-1 reduced in type 2 diabetes mellitus?
    Meier, Juris J.
    Nauck, Michael A.
    NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2008, 4 (11): : 606 - 607
  • [47] Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus in Italy: A Retrospective Cohort Study
    Marco Orsini Federici
    Janette McQuillan
    Giovanni Biricolti
    Serena Losi
    Jeremie Lebrec
    Catrina Richards
    Cristiana Miglio
    Kirsi Norrbacka
    Diabetes Therapy, 2018, 9 : 789 - 801
  • [48] Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus in Italy: A Retrospective Cohort Study
    Federici, Marco Orsini
    McQuillan, Janette
    Biricolti, Giovanni
    Losi, Serena
    Lebrec, Jeremie
    Richards, Catrina
    Miglio, Cristiana
    Norrbacka, Kirsi
    DIABETES THERAPY, 2018, 9 (02) : 789 - 801
  • [49] Utilization patterns of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus in Germany: a retrospective cohort study
    Otto, Thorsten
    Myland, Melissa
    Jung, Heike
    Lebrec, Jeremie
    Richter, Hartmut
    Norrbacka, Kirsi
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (05) : 893 - 901
  • [50] Glucagon-Like Peptide-1 Receptor Agonists for Diabetes Mellitus A Role in Cardiovascular Disease
    Smilowitz, Nathaniel R.
    Donnino, Robert
    Schwartzbard, Arthur
    CIRCULATION, 2014, 129 (22) : 2305 - 2312
12345